Current Medical Research and Opinion
February 1, 2024
Dakota Sicignano, Adrían V. Hernández, Benjamin Schiff et al.
19 citations
Critique the available systematic review and de novo assessment of the role of psychedelics in the treatment of alcohol use disorder. A systematic literature search of PubMed was completed from 1960 to 9/9/2023. We pooled randomized controlled trials comparing psychedelics to control therapy for the treatment of alcohol use disorder. At the first recorded follow-up, LSD [n = 3, Odds Ratio (OR)...
International Journal of Whole Person Care
January 29, 2024
Houman Farzin
Despite significant advances in symptom management for patients affected by serious illness, physicians lack effective legal treatments for individuals suffering from demoralization, death anxiety, and existential distress. Psilocybin-assisted psychotherapy employs psilocybin-containing mushrooms or synthetic psilocybin grounded in indigenous traditions and within the context of a therapeutic...
BMC Psychiatry
January 26, 2024
Laetitia Vanderijst, Felix Hever, Anne Buot et al.
11 citations
A significant number of individuals with alcohol use disorder remain unresponsive to currently available treatments, which calls for the development of new alternatives. In parallel, psilocybin-assisted therapy for alcohol use disorder has recently yielded promising preliminary results. Building on extant findings, the proposed study is set to evaluate the feasibility and preliminary clinical...
Journal of Indira Gandhi Institute Of Medical Sciences
2024
Rakesh Khanna
1 citation
Abstract A review of the literature on posttraumatic stress disorder (PTSD) suggests it to be a complex disorder with many contributing factors. The concept of PTSD has continued to evolve over time. A diagnosis of PTSD may be hard to get right. Studies suggest a wide variation in its presentation and diagnostic stability. It is tempting to explore the possibility of using chemicals that could...
Pharmacological Research
2024
David B. Yaden, Andrea P Berghella, Peter S. Hendricks et al.
12 citations
Substance use disorders (SUDs) have an enormous impact on public health. With classic psychedelic-assisted therapies showing initial promise in treating multiple SUDs, it is possible that these treatments will become legally available options for patients with SUDs in the future. This article highlights how classic psychedelic-assisted therapies might be integrated into current clinical...
Drug Design, Development and Therapy
2024
Sarah A Norring, Michael G Spigarelli
22 citations
Psilocybin, a tryptamine psychedelic, has been touted in the media both historically and recently as a potential game-changing mental health therapeutic. ClinicalTrials.gov has over one hundred and thirty psilocybin clinical trials listed covering the last twenty years. The single most important aspect of any therapeutic is to gain approval for marketing and thus enter the real-world phase of...
Frontiers in Psychiatry
2024
Marija Franka Žuljević, Nando Breški, Mariano Kaliterna et al.
6 citations
It is important to understand how mental health practitioners view recent findings on psychedelic-assisted psychotherapy (PAP) as there is potential this treatment may be incorporated into clinical practice. The aim of our study was to explore how psychiatrists who are not involved in psychedelic research and who are located in the European region perceive psychedelics and PAP. We conducted...
Revue de l'infirmiere
2024
Caroline Amberger, Laurent Szczesniak
In this article, we aim to highlight the specific role of nurses in the interdisciplinary model of psychedelic-assisted psychotherapy. We argue that the plural competencies of our profession are at the heart of future issues in psychiatry and the use of psychedelics.
Journal of addiction psychiatry
2024
Gianni Martire, Daniel Sipple, David Baron et al.
341 citations
Borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) share overlapping neurobiological mechanisms particularly reward deficiency and stress-like anti-reward processes. And so, BPD may be reclassified as a "traumatic personality stress disorder" (TPSD) with ensuing common therapeutic strategies that may stabilize dopaminergic reward function such as...
December 26, 2023
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas et al.
preprint
Background: The primary psychoactive drug in magic mushrooms, psilocybin induces profound alterations in consciousness through its action at the 5-HT2A receptor. This comprehensive review consolidates current research findings to elucidate the pharmacology, safety profile, and clinical applications of psilocybin.Areas of Uncertainty: Despite initial concerns that psilocybin could cause...